Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T23:02:35.348Z Has data issue: false hasContentIssue false
  • English
  • Français

Opioid withdrawal syndrome developing after long-term administration of naldemedine

Published online by Cambridge University Press:  11 May 2022

Mayumi Ishida Open the ORCID record for Mayumi Ishida [Opens in a new window] ,
Nozomu Uchida Open the ORCID record for Nozomu Uchida [Opens in a new window] ,
Akira Yabuno ,
Kosei Hasegawa ,
Naoki Mizunuma ,
Takao Takahashi  and
Hideki Onishi Open the ORCID record for Hideki Onishi [Opens in a new window]
Mayumi Ishida
Affiliation:
Departments of Psycho-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
Nozomu Uchida
Affiliation:
Department of General Medicine, Ogano Town Central Hospital, Hidaka, Saitama, Japan
Akira Yabuno
Affiliation:
Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
Kosei Hasegawa
Affiliation:
Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
Naoki Mizunuma
Affiliation:
Departments of Psycho-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan Tokyo Kagurazaka Law Firm, Tokyo, Japan
Takao Takahashi
Affiliation:
Departments of Supportive Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
Hideki Onishi*
Affiliation:
Departments of Psycho-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
*
Author for correspondence: Hideki Onishi, Department of Psycho-Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka City, Saitama 350-1298, Japan. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

One of the side effects of opioid administration is opioid-induced constipation (OIC). To address this side effect, the oral peripheral μ opioid receptor antagonist naldemedine was developed. As this drug does not cross the blood–brain barrier, it is thought that it does not lead to opioid withdrawal syndrome (OWS) with central nervous system symptoms.

Methods

Here, we report a cancer patient who presented with symptoms centered round anxiety and irritation 4 months after administration of naldemedine for OIC and who was diagnosed with OWS after close investigation.

Results

The patient was a 65-year-old female who had surgery for stage IB endometrial cancer 4 years previously, but experienced recurrence involving the pelvis 2 years later. Medical narcotics were used to control pain, but naldemedine was started to control subsequent constipation. When naldemedine-related OWS was suspected and the administration of naldemedine discontinued, the above symptoms disappeared within two days, and no recurrence was observed thereafter.

Significance of the results

For patients receiving naldemedine, it is necessary to consider the possibility of OWS regardless of the period of administration in order to maintain patient quality of life.

Keywords

CancerNaldemedineOpioid withdrawal syndromeOpioid-induced constipation
Type
Case Report
Information
Palliative & Supportive Care , Volume 20 , Issue 6 , December 2022 , pp. 897 - 899
Check for updates
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Publishing.Google Scholar
Coluzzi, F, Scerpa, MS and Pergolizzi, J (2020) Naldemedine: A new option for OIBD. Journal of Pain Research 13, 1209–1222.CrossRefGoogle ScholarPubMed
Ishida, M, Hiraoka, M, Yaguchi, A, et al. (2021) Naldemedine-induced opioid withdrawal syndrome with severe psychiatric symptoms in an advanced cervical cancer patient without brain metastasis. Palliative & Supportive Care, 1–3. doi: 10.1017/S1478951521001917.Google Scholar
Ishii, K, Yamashita, H, Yamaguchi, M, et al. (2020) Naldemedine-induced opioid withdrawal syndrome in a patient with breast cancer without brain metastasis. Internal Medicine 59(2), 293–296.CrossRefGoogle Scholar
Katakami, N, Harada, T, Murata, T, et al. (2017) Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 35(34), 3859–3866.CrossRefGoogle ScholarPubMed
Kawanishi, C, Onishi, H, Kato, D, et al. (2007) Unexpectedly high prevalence of akathisia in cancer patients. Palliative & Supportive Care 5(4), 351–354.CrossRefGoogle ScholarPubMed
Mesía, R, Virizuela Echaburu, JA, Gómez, J, et al. (2019) Opioid-induced constipation in oncological patients: New strategies of management. Current Treatment Options in Oncology 20(12), 91.CrossRefGoogle ScholarPubMed
Nomura, H, Aoki, D, Takahashi, F, et al. (2011) Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: A Japanese Gynecologic Oncology Group Study (JGOG2041). Annals of Oncology 22(3), 636–642.CrossRefGoogle Scholar
Webster, LR, Nalamachu, S, Morlion, B, et al. (2018) Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: A randomized, double-blind, placebo-controlled phase 3 study. Pain 159(5), 987–994.CrossRefGoogle ScholarPubMed
Wesson, DR and Ling, W (2003) The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs 35(2), 253–259.CrossRefGoogle Scholar